Vaccines
Strategies for chlamydial vaccines have been proposed that would boost an immune response, specifically the T-helper type 1 (Th1) response, to Chlamydia trachomatis. Select chlamydial proteins, including structural, membrane, and secretory proteins, such as the major outer-membrane protein, have been proposed as sub-unit vaccine candidates.[48]Pal S, Peterson EM, Rappuoli R, et al. Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge. Vaccine. 2006 Feb 6;24(6):766-75.
http://www.ncbi.nlm.nih.gov/pubmed/16199110?tool=bestpractice.com
[49]Singh SR, Hulett K, Pillai SR, et al. Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection. Vaccine. 2006 Feb 20;24(8):1213-24.
http://www.ncbi.nlm.nih.gov/pubmed/16194585?tool=bestpractice.com
An effective vector or adjuvant, however, has yet to be demonstrated. Likewise, effectiveness of such a vaccine for LGV genovars/serovars, as well as other manifestations of C trachomatis infection, remains to be investigated.[50]Igietseme JU, Black CM, Caldwell HD. Chlamydial vaccines, strategies and status. BioDrugs. 2002;16(1):19-35.
http://www.ncbi.nlm.nih.gov/pubmed/11908999?tool=bestpractice.com